Skip to main content
. 2012 Aug 2;2012:264854. doi: 10.1155/2012/264854

Table 1.

Baseline characteristics.

Variable n (%) Mean (SD)
Age (years; N = 2822) 46.4 (10.0)
Gender: female (N = 2824) 2050 (72.6)
Currently unable to work a (N = 2825) 1266 (44.8)
Duration of inability to work in the last 12 months (weeks; N = 2732) 7.8 (13.5)
Age at onset of depression (years; N = 2779) 37.2 (11.7)
Time since onset of depression (years; N = 2777) 9.2 (9.4)
Any hospitalization during the last 12 months (N = 2802) 316 (11.2)
Any suicide attempt during the last 12 months (N = 2793) 74 (2.6)
Duloxetine starting dose (N = 2816)
 30 mg 2051 (72.6)
 60 mg 756 (26.8)
Reason to start or change to duloxetine (N = 2825)
 Inadequate efficacy of pretreatment 1365 (48.3)
 Initial treatment 1350 (47.8)
 Patient decision 412 (14.6)
 Inadequate tolerability of pretreatment 314 (11.1)
History of antidepressant therapy in the last week (N = 2825) yes 1611 (57.0)
 No antidepressant therapy 1214 (43.0)
 Single antidepressant treatment 1219 (43.2)
 Most common (>2% of patients) single antidepressant therapies:
  Tricyclic antidepressant 515 (18.2)
  Selective serotonin reuptake inhibitor 410 (14.5)
  Noradrenergic and specific serotonergic antidepressant 126 (4.5)
  Selective serotonin and noradrenaline reuptake inhibitor 74 (2.6)
  Multiple antidepressant treatment 392 (13.9)
Patients with overall pain VAS >30 mm 2185 (79.4)
Any permanent pain medication (N = 2813) 769 (27.2)
Any on demand pain medication in the last 12 months (N = 2801) 1744 (61.7)
Any concomitant somatic diseases (N = 2825) 1813 (64.2)
 Most common (>9% of patients) concomitant somatic diseases:b
  Muscle and skeleton diseases 871 (30.8)
  Hypertension 573 (20.3)
  Allergies 306 (10.8)
  Metabolic diseases 277 (9.8)
  Gastrointestinal diseases 275 (9.7)
  Neurologic diseases 261 (9.2)

N: number of patients with available data; n: number of patients in category; SD: standard deviation.

aAnswer “yes” to the question “Is the patient unable to work today?”.

bAs selected from the check list.